Explore the phase 3 mRNA vaccine results and their implications for melanoma treatment and prevention.

Daraxorasib (Rasonque) is approved for metastatic pancreatic ductal adenocarcinoma, offering new treatment options for patients.

FDA approves zanidatamab for HER2-positive gastroesophageal cancer in frontline settings, offering a new treatment option for patients.

FDA approves lutetium Lu 177 vipivotide tetraxetan plus ARPI for metastatic hormone-sensitive prostate cancer, expanding treatment options.

The LungTIME-C01 study linking immunochemotherapy timing to survival in lung cancer was retracted. Learn what this means for treatment scheduling.

The American Society of Clinical Oncology issued its first guidelines for the use of blood-based ctDNA testing in diagnosis, therapy selection, surveillance, and prognosis in solid tumors and lymphoma. Among the key recommendations is that ctDNA should be used as a complementary tool versus a replacement for standard testing.

AYA cancer patients with sarcoma may not know resources, including palliative care, are available, and may resist them when offered.

An analysis of more than 200 hospitals found a very high mortality rate in non–COVID-19 ICU patients with invasive candidiasis.

In a single-arm, 2-stage study, tofacitinib reduced irAE rates, suggesting its potential as a bridging therapy to resolve irAEs and enable resumption of ICI treatment (Abstract 81). Randomized clinical trials involving multiple study centers and comparisons with standard glucocorticoid therapy are needed to further explore tofacitinib for addressing irAEs.

The latest findings from ASCO 2026 show how new treatment paradigms are shifting in early-stage breast cancer.

The PROTEUS trial shows that perioperative androgen receptor pathway inhibitor therapy improves metastasis-free survival in high-risk localized prostate cancer.

DISC-0974 produces durable hematologic responses in the ongoing phase 2 RALLY-MF trial in patients with myelofibrosis and anemia, indicating potential for benefit in a group of patients for whom no U.S. Food and Drug Administration–approved anemia treatment currently exists, despite the prevalence of inflammation and anemia in this population (Abstract 6501).

The ASCO Annual Meeting features the latest research news and policy updates across oncology. PROTEUS trial data show that patients with high-risk localized prostate cancer treated before and after surgery with an ARPI and ADT had a 20% greater…

Bupropion produces moderate reductions in fatigue in patients with cancer, particularly among women, when compared with a placebo, according to findings from a community-based, phase 3 trial (LBA12003).

Past Young Investigator Award and Career Development Award recipients describe what is possible in research today compared to when they started.

Innovation starts with one question or one incremental change at a time, and Conquer Cancer, the ASCO Foundation, supports researchers at all career phases in pursuit of these innovations.

Antibiotic therapy findings show dalbavancin effective and convenient for certain patients with Staphylococcus aureus infections.

A study presented at the 2024 American Society of Clinical Oncology (ASCO) Quality Care Symposium showed a sixfold increase in patients requiring drug switches because of payer step edits over the course of the past three years, with each switch…

Screening patients with cancer for financial toxicity is feasible, but experts say it should be thoughtfully integrated into oncology practice workflows with quality of life in mind and appropriate interventions in place. Details of one such…

Editor’s Note: Our coding and reimbursement column shows oncologists how to avoid headaches and maximize revenue by helping billing staff report accurate claims. Each year, oncology practices eagerly await Current Procedural Terminology (CPT) changes…